Chemomab Therapeutics | 20-F: Registration statement / Annual report / Transition report
Mar 28 06:14 ET
Chemomab Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-OrbiMed Israel BioFund GP Limited Partnership(16.0%),OrbiMed Israel GP Ltd.(16.0%), etc.
Mar 11 19:23 ET
Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Mar 7 07:04 ET
Chemomab Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Jan 3 00:00 ET
Chemomab Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-OrbiMed Israel BioFund GP Limited Partnership(18.3%),OrbiMed Israel GP Ltd.(18.3%), etc.
Nov 15, 2023 16:35 ET
Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Nov 9, 2023 08:00 ET
Chemomab Therapeutics | EFFECT: Others
Nov 6, 2023 00:15 ET
Chemomab Therapeutics | CORRESP: CORRESP
Nov 1, 2023 16:05 ET
Chemomab Therapeutics | F-3/A: Registration statement for specified transactions by certain foreign private issuers (Amendment)
Oct 30, 2023 08:33 ET
Chemomab Therapeutics | F-3: Registration statement for specified transactions by certain foreign private issuers
Oct 16, 2023 16:25 ET
Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Aug 14, 2023 08:05 ET
Chemomab Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Aug 8, 2023 06:00 ET
Chemomab Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Darvish Nissim
Jul 5, 2023 17:48 ET
Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Jul 3, 2023 15:49 ET
Chemomab Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Quigley Jill M.
Jun 20, 2023 06:03 ET
Chemomab Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Financial Officer Fatal Sigal
Jun 16, 2023 16:03 ET
Chemomab Therapeutics | 8-K: Current report
Jun 16, 2023 16:01 ET
Chemomab Therapeutics | 3: Initial statement of beneficial ownership of securities-Chief Financial Officer Fatal Sigal
Jun 5, 2023 16:54 ET
Chemomab Therapeutics | 8-K: Current report
Jun 5, 2023 07:00 ET
Chemomab Therapeutics | RW: Registration Withdrawal Request
Jun 2, 2023 16:02 ET
No Data
No Data